Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

GSD extends partnership with Fujirebio for Cyfra assays

Gold Standard Diagnostics (GSD) has extended its relationship with Fujirebio Diagnostics for the distribution of its Cyfra 21-1 EIA assays in the US.

Fujirebio provides in vitro diagnostics, and biomarkers and is mailnly focused on oncology markers.

The Cyfra 21-1 EIA kit is used to quantitatively determine soluble cytokeratin 19 fragments in human serum.

Cyfra 21-1 EIA kit is also used to monitor disease progression during the course of disease and treatment in patients with lung cancer.

David Grenache, a medical director at Arup Laboratories, said FDA clearance of Cyfra 21-1 allows laboratories in the US the opportunity to provide a valuable diagnostic tool to oncologists in the management of lung cancer.

GSD also distributes Fujirebio’s HE4 EIA, Multi-Constituent Tumor Marker control and Vitamin D control.